1 March 2016 in Journal of Integrative Neuroscience
1 January 2019 in Reviews in Cardiovascular Medicine
Currently, the percentage of non-specific myocardial lesions of non-inflammatory genesis has significantly increased in the structure of cardiovascular diseases in children and adolescents. Cardiomyopathies are a cluster of myocardial diseases that have become more of interest by cardiologists, morphologists, geneticists, and cardiac surgeons. Cardiomyopathies in children are regarded as a severe pathology characterized by a progressive course, resistance to therapy, and result in an unfavourable prognosis. The current article presents data from international publications dedicated to cardiomyopathy diagnostics in children. This article deals with terminology issues in compliance with international disease classification, primary diagnostic criteria of non-coronary myocardium pathology, and modern methods of diagnostics and pharmacotherapy.
1 June 2012 in Journal of Integrative Neuroscience
31 May 2024 in Journal of Arrhythmology
The use of early rhythm control and catheter ablation is an actively developing direction in the treatment of atrial fibrillation. The review presents studies published from 2021 to 2024, the results of which have the potential to strengthen evidence on the early rhythm control and allow to expand the recommendations for the use of catheter ablation with evidencebased medicine principles.
29 June 2026 in Kuban Scientific Medical Bulletin
Background. In the Russian Federation, clinical experience with flecainide remains limited due to its relatively recent regulatory approval. Therefore, it is essential to evaluate the current safety and tolerability of this drug for the prevention of atrial fibrillation by synthesizing recent data. Objective . To evaluate the safety and tolerability of flecainide for the prevention of atrial fibrillation in adult patients using data from published randomized controlled trials. Methods . A systematic search of the PubMed (MEDLINE, PreMEDLINE, NLM) and Cochrane Library databases was conducted following the PRISMA guidelines for studies published between January 2015 and March 2026. This review included randomized controlled trials evaluating flecainide administration in adult patients for long-term rhythm control of atrial fibrillation. To obtain a pooled effect size, the meta-analysis incorporated risk ratio values with 95% confidence intervals for the safety outcomes. Results . A total of 933 articles were screened, resulting in the inclusion of five studies (1265 patients). Two of the five randomized controlled trials included in the meta-analysis separately evaluated the primary safety outcome and adverse events. In the remaining three studies, the authors reported flecainide-related adverse events, including proarrhythmia, as part of safety outcomes. Based on a random-effects model using the inverse variance method to compare risk ratios, no statistically significant differences in safety outcomes were found between the flecainide-treated group and the control group. The risk ratio was 0.69, with a 95% confidence interval of 0.36 to 1.31. Conclusion . The results of this meta-analysis demonstrate the relative safety of flecainide when patients are appropriately selected and proarrhythmic risks are carefully monitored. However, these findings should be interpreted with caution due to several limitations and the necessity of an individualized approach for patients with multiple comorbidities in real-world clinical practice.
30 September 2019 in Research Results in Pharmacology
Introduction: There are almost no studies characterizing the integrative level of blood pressure (BP) regulation. Materials and methods: 277 people of both genders aged 58.6±6.4 with stage II hypertension disease were randomized into six groups. The monotherapy of hypertension disease was conducted in five groups, using nebivolol, lisinopril, indapamide, amlodipine, and losartan. The sixth group had a combined therapy (lisinopril/indapamide). The therapy effectiveness was assessed at four levels of blood pressure regulation, using the following methods: 1) laser Doppler flowmetry, determination of the level of tumor necrosis factor-α and interleukin-10; 2) echocardiography and Doppler sonography, ultrasound examination of the renal blood flow, ECG, Holter monitoring of ECG; 3) an examination of the heart rate variability level and a quantitative assessment of beta-adrenoreception of erythrocyte cell membranes; 4) the regulatory and adaptive status was assessed, using the method of cardio-respiratory synchronism. Results and discussion: A more significant BP decrease was revealed during a combination therapy (by 20.4% of the baseline daily value). At the integrative level, an index of the regulatory and adaptive status (iRAS) increased in the treatment with lisinopril/indapamide combination (by 40.5%), amlodipine (by 40.5%), losartan (by 35.3%), and lisinopril (by 30.2%). Nebivolol administration resulted in a 13.5% decrease in iRAS. Indapamide therapy had no significant effect on iRAS. Conclusion: A comprehensive assessment of the blood pressure regulation system makes it possible to control the effectiveness of the therapy not only on a target organ or function, but also on the condition of the organism as an integral system.